Helios Small Cap Fund
The scheme seeks to generate long-term capital appreciation from a portfolio that is invested predominantly in equity and equity related securities of small cap companies
Growthvine rating: 1/5 — ranked #35 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹11.52 (as of 2026-11-13) |
|---|
| AUM | ₹1,885 Cr |
|---|
| Expense ratio | 1.77% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Alok Bahl |
|---|
| Exit load | 1% for redemption within 3 months |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −17.30% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 125.7% of NIFTY Smallcap 250's upside and — of its downside.
Market cap allocation
| Large cap | 2.1% |
|---|
| Mid cap | 17.8% |
|---|
| Small cap | 80.1% |
|---|
Concentration
| Top 5 holdings | 9.8% |
|---|
| Top 10 holdings | 18.4% |
|---|
| Total holdings | 98 |
|---|
| Index overlap | 19.7% |
|---|
| Active share | 80.3% |
|---|
Top holdings
- TREPS — 2.6%
- Ather Energy Limited — 2.2%
- SHADOWFAX TECHNOLOGIES LIMITED — 2.1%
- TIPS MUSIC LIMITED — 1.9%
- Multi Commodity Exchange of India Ltd — 1.8%
- Leela Palaces Hotels & Resorts Limited — 1.8%
- PVR INOX LIMITED — 1.8%
- Rentomojo Limited — 1.7%
- Honasa Consumer Limited — 1.7%
- One 97 Communications Limited — 1.7%
Top sectors
- Automobile — 13.0%
- Banking & Financial — 9.2%
- Pharma & Biotech — 7.8%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 17.3% | Q2 | #11 of 34 |